Balyasny Asset Management
RVNC

Balyasny Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Balyasny Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-140,100
Closed -$727K – 3375
2024
Q3 		$727K Buy
+140,100
New +$696K ﹤0.01% 2096

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's RVNC Position: Q4 2024 in Review

Balyasny Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 96,154 shares — an estimated $419K sold.

Balyasny Asset Management first reported a position in RVNC in Q1 2015 and held it in 8 quarters. The position peaked at $5.39M in Q3 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Balyasny Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Balyasny Asset Management sold 96,154 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $419K.
  • Balyasny Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
  • Balyasny Asset Management's Revance Therapeutics, Inc. position peaked at $5.39M in Q3 2023.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.